Janus Henderson Group PLC Decreases Stock Position in Cencora, Inc. (NYSE:COR)

Janus Henderson Group PLC lowered its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 54.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 413,437 shares of the company's stock after selling 502,541 shares during the period. Janus Henderson Group PLC owned about 0.21% of Cencora worth $93,055,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of COR. New Millennium Group LLC bought a new stake in shares of Cencora in the 2nd quarter valued at about $26,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora in the 2nd quarter valued at about $30,000. Concord Wealth Partners bought a new stake in shares of Cencora in the 3rd quarter valued at about $30,000. SYSTM Wealth Solutions LLC bought a new stake in shares of Cencora in the 2nd quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $41,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Down 1.6 %

Shares of COR stock traded down $4.03 during trading hours on Thursday, reaching $244.31. The company had a trading volume of 1,337,065 shares, compared to its average volume of 1,390,761. Cencora, Inc. has a 12 month low of $195.83 and a 12 month high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business has a fifty day simple moving average of $236.34 and a 200-day simple moving average of $233.11. The company has a market cap of $48.14 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 1.66 and a beta of 0.45.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is currently 29.29%.

Insider Activity

In related news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 93,018 shares of company stock worth $22,478,942 over the last 90 days. 15.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on COR shares. UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Finally, Bank of America reissued a "neutral" rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $276.80.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.